ARTICLE | Product Development
COVID-19: manufacturing mAbs in patients
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 3, 2020 12:48 AM UTC
Updated on Apr 3, 2020 at 8:47 PM UTC
The urgency and scale of the coronavirus outbreak could drive progress in an emerging therapeutic strategy suited to rapid development and distribution -- encoding of antibodies in RNA or DNA.
Neutralizing mAbs against SARS-CoV-2 have arisen as a leading approach among companies designing preclinical therapies for COVID-19. At least 20 groups have disclosed mAb programs (see “COVID-19 Therapies and Vaccines: Preclinical”). ...